NEUCYTE-FINAL LOGO.png

Visit

  • Grey LinkedIn Icon
  • Grey Twitter Icon

©2019 BY NEUCYTE, INC

Beyond iPSC Based Disease Models

A Translatable Drug Discovery Platform

for Status Epilepticus 

Epilepsy is a common neurological disorder characterized by recurrent spontaneous seizures.  Up to 40% of patients do not respond or develop resistance to available anti-epileptic drug treatments. The establishment of more translatable human cell-based assays can address the unmet need for new therapy strategies by complementing pre-clinical drug development to increase success rates in human patients. 

During this webinar, Dr Daniel Haag, Head of Neuroscience at NeuCyte, will share how the NeuCyte team has built an iPSC-derived neural in vitro platform with complex electrophysiology-based phenotypic readouts to evaluate the efficacy of novel compounds and approved AEDs (antiepileptic drugs) for the treatment of Status Epilepticus.  

Daniel

Haag

Head of Neuroscience and Co-Founder